Lpath is a biotech company focused on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States. LPTN’s lead product candidate, iSONEPTM, is currently in two clinical trials to evaluate the safety and potential efficacy for the treatment of Pigment Epithelial Detachment (PED) in wet AMD patients; and a phase 2 study to determine the safety and efficacy of iSONEP given alone or in combination with Lucentis® or Avastin® in subjects with wet Age-related Macular Degeneration (AMD). For more information visit the company’s Web site at: www.lpath.com
Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.
Let us hear your thoughts below: